Genelux Corp GNLX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $1.90
- Day Range
- $1.83–1.94
- 52-Week Range
- $1.77–6.01
- Bid/Ask
- $1.83 / $1.87
- Shares Outstanding
- 45.25M
- Market Cap
- $83.70M
- Volume/Avg
- 19,420 / 332,390
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 9,793.81
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 26
- Website
- https://www.genelux.com
Valuation
Metric | GNLX |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 5.32 |
Price/Sales | 9,793.81 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | GNLX |
|---|---|
Quick Ratio | 2.33 |
Current Ratio | 2.39 |
Interest Coverage | — |
Quick Ratio
GNLX
Profitability
Metric | GNLX |
|---|---|
Return on Assets (Normalized) | −106.39% |
Return on Equity (Normalized) | −154.14% |
Return on Invested Capital (Normalized) | −143.29% |
Return on Assets
GNLX
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|Lb%l>hL | LOCK|?R#^ | $138B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|TBS<%?P | LOCK|!rSR | $98B | |||
| Moderna Inc MRNA | LOCK|?$c!>> | LOCK|Rlh | $94B | |||
| argenx SE ADR ARGX | LOCK|M$#cP^% | LOCK|k@f | $62B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|@<K>NX | LOCK|r& | $50B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|hG@ych>r | LOCK|Q#x! | $31B | |||
| Incyte Corp INCY | LOCK|^Q?$Tx | LOCK|zY& | $25B | |||
| BioNTech SE ADR BNTX | LOCK|^!!LJ&^ | LOCK|^W | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|vRD%#tt | LOCK|##$%J | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|XG$pyc | LOCK|Pbj | $15B |
United States